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Abstract
Influenza A virus uses its host transcription machinery to facilitate viral RNA synthesis, an event that is associated
with cellular RNA polymerase II (RNAPII). In this study, various RNAPII transcription inhibitors were used to
investigate the effect of RNAPII phosphorylation status on viral RNA transcription. A low concentration of DNA
intercalators, such as actinomycin D (ActD), was found to stimulate viral polymerase activity and virus replication.
This effect was not observed in cells treated with RNAPII kinase inhibitors. In addition, the loss of RNAPIIa in
infected cells was due to the shift of nonphosphorylated RNAPII (RNAPIIa) to hyperphosphorylated RNAPII (RNAPIIo).
Introduction
The C-terminal domain (CTD) of RNAPII is important for
cellular mRNA transcription, and interacts with several
post-transcriptional factors for RNA maturation and
nuclear export. The phosphorylation status of CTD is
known to be a critical regulatory checkpoint for RNAPII
transcription [1]. The hyperphosphorylated (transcription-
ally engaged) form of RNAPII is designated as RNAPIIo,
whereas its nonphosphorylated (transcriptionally inactive)
form is designated as RNAPIIa. At the early stage of tran-
scription, free RNAPIIa interacts with other general tran-
scription factors on cellular DNA promoters to form a
transcription pre-initiation complex, which is followed by
transcription initiation [2]. The newly initiated RNAPIIa
then proceeds to the promoter-proximal pause region, and
the paused RNAPIIa is subsequently hyperphosphorylated,
preferably on the serine 5 (Ser5) positions, by cyclin-
dependent kinase (Cdk) 7. As transcription elongation
proceeds, the serine 2 (Ser2) and Ser5 positions in the
CTD of RNAPII are hyperphosphorylated by Cdk9 [3] and
dephosphorylated by SCP1 [4], respectively. The Ser5-
phosphorylation helps to recruit enzymes to cap the nas-
cent RNA transcript, whereas the Ser2-phosphorylation
facilitates the conversion of RNAPII into a productive
elongating form.
Influenza viral RNA synthesis is dependent on its host
transcription machinery. Various RNAPII inhibitors such
as a-amantin and actinomycin D (ActD) have been shown
to inhibit influenza virus replication [5-7]. Chan et al.
demonstrated that the influenza viral polymerase complex
can inhibit RNAPII transcription elongation, but not
initiation [8], a phenomenon that is similar to the tran-
scriptional arrest of RNAPII. This transcriptional arrest
may be related to direct interaction between vRNP and
Ser5-phosphorylated RNAPIIo [9]. It has also been demon-
strated that a robust polymerase complex is more capable
of binding to RNAPIIo [10]. Recently, influenza viral poly-
merase has been proposed to induce the direct degrada-
tion of RNAPIIa [11-13], thereby inhibiting host gene
expression. The overall conclusion of these previous find-
ings is that RNAPII plays a critical role in viral RNA tran-
scription, although little is known about the mechanism
responsible for RNAPIIa disappearance during infection.
Moreover, the role played by the post-translation modifi-
cation of RNAPII in viral RNA synthesis is yet to be deter-
mined. In this study, we would like to determine the effect
of various RNAPII inhibitors on influenza viral polymerase
functions and virus replications. In particular, the inhibi-
tors used in this study are known to inhibit RNAPII via
different mechanisms and have different effects on the
phosphorylation status of RNAPII. It is of our interest to
use these chemicals to understand how the influenza virus
can utilize RNAPII to facilitate viral RNA synthesis.
Findings
This study examined the effects of various RNAPII tran-
scription inhibitors on viral RNA synthesis. A luciferase-
based influenza viral polymerase reporter assay [10] was
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treated cells. Transfected cells were first treated
with different RNAPII inhibitors at six hours post-
transfection and then tested for luciferase activity at 22
hours post-transfection (Figure 1). ActD, a DNA inter-
calator that is well-known to convert RNAIIa to RNA-
PIIo [14], was found to inhibit viral polymerase activity
at high concentrations (Figure 1A). Strikingly, however,
ActD at the low concentration range (~10 ng/ml) was
consistently found to stimulate viral polymerase activity
by 50%. This ActD activation effect was previously
observed in genes containing an HIV-1 LTR sequence
[15]. ActD at this low concentration range can increase
the RNAPIIo population by creating temporary tran-
scriptional obstacles for RNAPIIo [15,16], which suggests
that the blockage of RNAPIIo transcription may facilitate
viral gene expression. This activation effect was further
confirmed by the use of another DNA intercalator, ethi-
dium bromide (EtBr), to induce the stalling of RNAPIIo.
A ss h o w ni nF i g u r e1 B ,at w o - f o l di n c r e a s ei nv i r a l
polymerase activity was observed in cells treated with
2.5 μg/ml of EtBr. In contrast, Cdk inhibitors 5,6-dichloro-
benzimidazole riboside (DRB) and 1-(5’-isoquinolinesulfo-
nyl)-2-methylpiperazine (H7), which can inhibit the
phosphorylation of RNAPIIa, failed to exhibit similar sti-
mulating effects on such activity (Figures 1C and 1D).
Using a GFP expression plasmid under the control of a
C M Vp r o m o t e ra sac o n t r o l ,i tw a st h e nc o n f i r m e dt h a t
these DNA intercalators in the concentrations under
investigation cannot enhance cellular RNAPII transcrip-
tion [15] (Additional File 1). In short, these results suggest
that influenza viral polymerase may require RNAPIIo,o r
the formation of RNAPIIo, for efficient viral transcription.
To test whether the unexpected enhancement effect of
ActD on viral polymerase has any impact on virus repli-
cation, MDCK cells were treated with various concen-
trations of ActD immediately after viral infection.
Briefly, MDCK cells were infected with A/WSN/33 for
one hour. In order to observe the maximal effect of this
drug on a single round of virus replication, cells were
super-infected with the virus at an MOI of 10. The
uninfected virus in the inoculums was inactivated by a
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Figure 1 Effects of RNAPII transcription inhibitors on influenza viral polymerase activity. 293T cells were transfected with A/WSN/33 PB2,
PB1, PA and NP protein expression plasmids and a pPolI Luc-RT RNA expression plasmid, as described previously [10]. The transfected cells were
then washed and replenished with media containing various concentrations of ActD (A), DRB (B), H7 (C) or EtBr (D) at six hours post-transfection.
The luciferase activity of the drug-treated cells was measured with a luminometer (Victor3, PerkinElmer) using a Steady-Glo luciferase reagent
(Promega) at 22 hours post-transfection. The luciferase activity of the mock-treated cells was taken as 100% polymerase activity. Data ± SE were
obtained from the triplicate experiments.
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Page 2 of 5short acidic buffer wash after infection. The amount of
progeny viral particles generated from the treated cells
at six (i.e. <1 virus replication) and eight (i.e. ~1 virus
replication cycle) hours post-infection was determined.
As shown in Figure 2A, influenza virus replication can
be abolished by treating infected cells with 1 μg/ml of
ActD, as expected [17]. Unlike the results obtained from
the transfected 293T cells used in the aforementioned
luciferase assay, MDCK cells treated with 100 ng/ml of
ActD can still support virus replication. These observa-
tions suggested these cell lines might have different tol-
erances to the drug. Nonetheless, a low concentration of
ActD was also found to enhance virus replication signif-
icantly (p < 0.05). For example, the viral titre from cells
treated with 1 ng/ml of ActD at 8 hours post-infection
was found to be 2.2-fold higher than that of the mock
control. This stimulating effect, however, was not
observed in cells treated with DRB (Figure 2B). These
results indicate that different RNAPII inhibitors may
have different effects on virus replication and that these
differential effects may be due to different phosphoryla-
tion statuses of CTD (see below).
ActD intercalates DNA, and inhibits transcription
elongation by immobilizing the RNAIIPo on DNA
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Figure 2 Actinomycin D stimulates virus replication at early post-infection stage. MDCK cells were infected with A/WSN/33 at an MOI of 10 for
one hour, followed by a short 0.9% saline (pH 2.0) wash. The infected cells were then cultured in media supplemented with various concentrations of
ActD (A) or DRB (B). Viral culture supernatants were harvested at the indicated time points, and viral titres were titrated using standard plaque assay
techniques. Data ± SE were obtained from the triplicate experiments. Asterisk: viral titres that were significantly different from their corresponding
controls (p < 0.05).
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that inhibits the phosphorylation of RNAPIIa [19]. We
therefore took advantage of the distinct inhibitory
mechanisms of these two chemicals to investigate the
disappearance of RNAPIIa in influenza virus-infected
cells. MDCK cells were pre-incubated with ActD or
DRB at a predetermined concentration known to have
prominent change on CTD phosphorylation in the
Western blot analyses (Figure 3A, lanes 1- 4), but
without severely affecting the viral RNA transcription
and replication in the subsequent viral infection (Fig-
ure 3B, lanes 2 and 1). As shown in Figure 3A (lane
8), influenza viral infection promoted the disappear-
ance of RNAPIIa in the untreated cells as described in
previous investigations [10,11,13]. Cells treated with 1
μg/ml of ActD had a complete conversion of RNAPIIa
to RNAPIIo ( F i g u r e3 A ,l a n e s5a n d6 ) ,b u tf a i l e dt o
support viral RNA synthesis ( 3B, lane 3). Cells treated
with 50 ng/ml of ActD had reduced levels of RNAPIIa
(Figure 3A, lane 1) and remained able to support viral
RNA synthesis (Figure 3B, lane 2). It should be noted
that viral infection is still capable of inducing the dis-
appearance RNAPIIa at this concentration of ActD
(Figure 3A; compare lanes 1 and 2), suggesting that
the phophorylation of RNAPIIa is essential for virus
replication. On the other hand, viral transcription and
replication products were detected in the infected cells
treated with 75 μM of DRB (Figure 3B, lane 1),
although the treatment was found to inhibit
the disappearance of RNAPIIa induced by the infection
(Figure 3A, lane 4). Previous co-immunoprecitation
work has demonstrated that viral polymerase interacts
specifically with Ser5-phosphorylated, but not Ser2-
phophorylated, RNAPIIo [9]. Hence, the results of both
the current and previous studies suggest that viral
polymerase may need to recruit and arrest newly
formed RNAPIIo (i.e., Ser-5-phophorylated RNAPII),
but not the actively elongating form of RNAPIIo (i.e.,
Ser-2-phophorylated RNAPII), for viral RNA
transcription.
Conclusion
Influenza A virus infection results in a significant loss of
transcriptionally inactive RNAPII (RNAPIIa) [11-13].
However, as influenza polymerase requires capped pri-
mers snatched from the host nuclear RNA for its viral
RNA transcription [20-22], a direct induction of RNA-
PIIa degradation via the viral polymerase may not favour
such a transcription. In this study, it has been demon-
s t r a t e dh e r et h a tt h ed i s a p p e a r a n c eo fR N A P I I a is
related to a shift of RNAPIIa to RNAPIIo (Figure 3). In
addition, this conversion of RNAPIIa to RNAPIIo is
found to be important to viral RNA synthesis, which
suggests that newly synthesized RNAPIIo may be a criti-
cal determinant of viral transcription. RNAPII can be
subjected to various post-translational modifications [1].
Further investigation of the post-translational modifica-
tion of RNAPII in influenza virus-infected cells may
help us to better understand the transcription and repli-
cation of influenza viruses.
Additional material
Additional file 1: Effects of EtBr on GFP expression. 293T cells were
transfected with GFP expressing plasmid under the control of a CMV
promoter. The transfected cells were then washed and replenished with
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Figure 3 Effects of ActD and DRB on RNAPII phosphorylation and viral transcription. Prior to infection, MDCK cells were treated with ActD
or DRB in MEM supplemented with 10% foetal calf serum and 1% penicillin/streptomycin for three hours, followed by infection with A/WSN/33
(MOI = 2) in the presence of the corresponding drugs. The infected cells were cultured in a medium containing ActD or DRB, and culture
supernatants were harvested at six hours post-infection. (A) Effects of ActD and DRB on RNAPII phosphorylation in infected cells. Total cell lysates
were harvested and studied by western blot analysis using anti-RNAPII (N20) and anti-b actin (C4) antibodies (Santa Cruz Biotechnology, Santa
Cruz, USA). The signals for RNAPIIo and RNAPIIa are indicated. Beta-actin was used as the loading control. (B) Effects of ActD and DRB on viral
RNA synthesis. Total RNA was analyzed with primer extension assays, as described previously (10). The bands representing the mRNA, cRNA and
vRNA of segment 5 are marked by arrows.
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Page 4 of 5media containing various concentrations of EtBr at six hours post-
transfection. The GFP signal was measured with a luminometer (Victor3,
PerkinElmer) at 22 hours post-transfection. The GFP signal of the mock-
treated cells was taken as 100% polymerase activity. Data ± SE were
obtained from the triplicate experiments.
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